


UROonco25

Steered by the EAU Section of Oncological Urology

19-21 June 2025, Seville, Spain

www.uroonco25.org



An application has been made to the EACCME® for CME accreditation of this event

Welcome to EAU UROonco

Thursday 19 June 14:00 - 14:15	Location	Auditorium
-----------------------------------	----------	------------

Welcome word

- A. Stenzl, Tübingen (DE)
- A. Volpe, Novara (IT)

Prostate cancer I: Rapid-fire debates - Controversies in prostate cancer

Plenary Session

Thursday 19 June 14:15 - 15:45	Location	Auditorium
	Chairs	J. Gómez Rivas, Madrid (ES) F. Sanguedolce, Barcelona (ES)

14:15 - 14:17	Welcome and introduction
14:17 - 14:39	What will the best strategy be for prostate cancer screening?
14:17 - 14:23	We should start with MRI H.U. Ahmed, London (GB)
14:23 - 14:29	PSA will always come first P. Albers, Düsseldorf (DE)
14:29 - 14:39	Discussion/Q&A
14:39 - 15:01	Optimal sampling in biopsy-naïve men with elevated PSA
14:39 - 14:45	Go target + perilesional F. Sanguedolce, Barcelona (ES)
14:45 - 14:51	Go target + systematic G. Marra, Turin (IT)
14:51 - 15:01	Discussion/Q&A
15:01 - 15:23	Active surveillance for WHO/ISUP Grade Group 2 prostate cancer
15:01 - 15:07	To be offered to most men To be confirmed
15:07 - 15:13	Definitely not an option A. Cimadamore, Udine (IT)
15:13 - 15:23	Discussion/Q&A
15:23 - 15:45	Should we perform an extended PLND for prostate cancer in 2025?
15:23 - 15:29	Yes, because... K. Touijer, New York (US)
15:29 - 15:35	Forget it! D. Tilki, Hamburg (DE)
15:35 - 15:45	Discussion/Q&A

Non-muscle invasive bladder cancer: What's new?

Plenary Session

Thursday 19 June 16:45 - 18:15	Location	Auditorium
	Chairs	J. Aning, Bristol (GB)
		M. Moschini, Milan (IT)

16:45 - 16:47	Welcome
16:47 - 16:57	State-of-the-art lecture Low-risk NMIBC: Deintensification protocols, surveillance and biomarkers role R. Contieri, Pieve Emanuele (IT)
16:57 - 17:00	Discussion/Q&A
17:00 - 17:31	Debate Intermediate risk NMIBC with several LG recurrence: What do I do?
17:00 - 17:05	Case presentation To be confirmed
17:05 - 17:12	MMC: Rational, dosing, frequency A. Mari, Florence (IT)
17:12 - 17:19	BCG: Rational, dosing, frequency B. Pradère, Toulouse (FR)
17:19 - 17:31	Discussion
17:31 - 17:41	State-of-the-art lecture Recurrence after BCG - BCG unresponsive, where do we stand: Optimal treatment sequence P. Gontero, Turin (IT)
17:41 - 17:44	Discussion/Q&A
17:44 - 18:15	Debate Surveillance for HG NMIBC: Are we ready to replace flexible cystoscopy? Biomarkers are running the show
17:44 - 17:49	Case presentation To be confirmed
17:49 - 17:56	Yes, biomarkers are running the show To be confirmed
17:56 - 18:03	No, flexible cystoscopy is here to stay E.N. Xylinas, Paris (FR)
18:03 - 18:15	Discussion

Prostate cancer II

Plenary Session

Friday 20 June 08:00 - 09:30	Location	Auditorium
	Chairs	G. Gandaglia, Milan (IT) J. Gómez Rivas, Madrid (ES)
08:00 - 09:00	Nightmares in localised prostate cancer	
08:00 - 08:20	Active surveillance (case presentation, voting and discussion) R. Van Den Bergh, Rotterdam (NL)	
08:20 - 08:40	Radical prostatectomy (case presentation, voting and discussion) F. Montorsi, Milan (IT)	
08:40 - 09:00	Radiation therapy (case presentation, voting and discussion) To be confirmed	
09:00 - 09:30	Clinical case discussion Stage migration using PSMA PET/CT: Are we losing surgery as an option for cure?	
09:00 - 09:05	Case presentation C. Fede Spicchiale, Glasgow (GB)	
09:05 - 09:30	Panel discussion Panel A. Briganti, Milan (IT) I. Burger, Baden (CH) G. De Meerleer, Leuven (BE) K. Touijer, New York (US)	

Update session I: Renal cancer

Friday 20 June 08:30 - 09:30	Location	Session room II
	Moderators	A. Alcaraz, Barcelona (ES) R. Campi, Florence (IT) C. Palumbo, Novara (IT)

Case I To be confirmed

Case II To be confirmed

Renal cancer I: Localised

Plenary Session

Friday 20 June 10:15 - 12:00	Location	Auditorium
	Chairs	A. Alcaraz, Barcelona (ES) A. Volpe, Novara (IT)

10:15 - 10:35	Trials & updates: Renal cancer localised	
10:15 - 10:25	To be confirmed	To be confirmed
10:25 - 10:35	To be confirmed	To be confirmed
10:35 - 10:50	State-of-the-art lecture	Stereotactic body radiation therapy for primary RCC To be confirmed
10:50 - 10:55	Discussion	
10:55 - 11:35	Video session	Surgical management of cystic renal tumours
	Panel	J-C. Bernhard, Bordeaux (FR) To be confirmed To be confirmed To be confirmed
	Provoker	A. Alcaraz, Barcelona (ES)
11:35 - 12:00	Panel discussion	Management of multifocal renal masses
	Case presenter	J. Correia, Porto (PT)
	Panel	J-C. Bernhard, Bordeaux (FR) To be confirmed R. Campi, Florence (IT) To be confirmed

Update session I: Bladder cancer

Friday 20 June 10:15 - 11:15	Location	Session room II
	Moderators	J. Aning, Bristol (GB)
		To be confirmed
		M. Moschini, Milan (IT)

Case I To be confirmed

Case II To be confirmed

Update session I: Prostate cancer

Friday 20 June 11:30 - 12:30	Location	Session room II
	Moderators	J. Gómez Rivas, Madrid (ES) R. Nicoletti, Florence (IT)
		To be confirmed

Case I To be confirmed

Case II To be confirmed

Diagnostic dilemmas in testicular cancer: From molecular markers to modern imaging

Plenary Session

Friday 20 June 12:00 - 13:00	Location	Auditorium
	Chairs	O.R. Brouwer, Amsterdam (NL) C. Fankhauser, Lucerne (CH)
12:00 - 12:27	Equivocal testicular mass	
12:00 - 12:02	Case presentation When ultrasound/AFP/HCG leaves us guessing K. Mehra, Bhopal (IN)	
12:02 - 12:12	MRI in testicular cancer: Game-changer or over-promise? A. Tsili, Ioannina (GR)	
12:12 - 12:22	Liquid biopsy revolution: miRNA as the new diagnostic frontier J. Lobo, Porto (PT)	
12:22 - 12:27	Intraoperative frozen section: Optimising decision-making in organ-sparing surgery or just intraoperative delay? To be confirmed	
12:27 - 12:53	Equivocal retroperitoneal lesions	
12:27 - 12:29	Case presentation 50 Shades of grey: Navigating ambiguous retroperitoneal findings K. Mehra, Bhopal (IN)	
12:29 - 12:37	Grey zones or colours in retroperitoneal imaging, FDG-PET, FAPI-PET, MRI or repeated CT for suspicious lesions To be confirmed	
12:37 - 12:45	When and how to biopsy retroperitoneal lymph nodes To be confirmed	
12:45 - 12:53	Beyond imaging: miRNA as the missing piece in stage II decision-making J. Lobo, Porto (PT)	
12:53 - 13:00	Discussion The ideal diagnostic workflows in equivocal testicular and retroperitoneal lesions	
	Panel	To be confirmed To be confirmed J. Lobo, Porto (PT) K. Mehra, Bhopal (IN) A. Tsili, Ioannina (GR)

Prostate cancer III

Plenary Session

Friday 20 June 14:00 - 15:30	Location	Auditorium
	Chairs	G. Giannarini, Udine (IT)
		B. Tombal, Brussels (BE)

14:00 - 14:10

State-of-the-art lecture Artificial intelligence and prostate cancer: Challenges and opportunities
P. Dasgupta, London (GB)

14:10 - 14:20

Discussion and Q&A

14:20 - 14:50

Clinical trial corner

14:20 - 14:30

ARANOTE
To be confirmed

14:30 - 14:40

LIBERTAS
To be confirmed

14:40 - 14:50

Case discussion: Trials put in practice

Case presenterB. Tombal, Brussels (BE)

Panel
To be confirmed
To be confirmed
To be confirmed

14:50 - 15:30

Nightmares in advanced prostate cancer

14:50 - 15:10

Local symptoms in castration-resistant prostate cancer (case presentation, voting and discussion)
To be confirmed

15:10 - 15:30

Systemic treatments (case presentation, voting and discussion)
I. Heidegger, Innsbruck (AT)

Update session II: Renal cancer

Friday 20 June 14:00 - 15:00	Location	Session room II
	Moderators	D. Amparore, Candiolo (IT) L. Marandino, London (GB) A. Volpe, Novara (IT)

Case I: To be confirmed

Case II To be confirmed

Advanced penile cancer: Surprising functional results after penile sparing surgery and ideal follow-up protocols

Plenary Session

Friday 20 June 15:30 - 16:30	Location	Auditorium
	Chairs	O.R. Brouwer, Amsterdam (NL) C. Fankhauser, Lucerne (CH)
15:30 - 15:32	Case presentation Balancing radical cure and organ preservation in localised penile cancer K. Mehra, Bhopal (IN)	
15:32 - 15:42	Digital beats digital: Does ultrasound trump the clinical exam during follow-up M.T.A. Vreeburg, Amsterdam (NL)	
15:42 - 15:52	Sexual functioning after penile cancer surgery K. de Ligt, Amsterdam (NL)	
15:52 - 15:54	pN3 case, all is lost? K. Mehra, Bhopal (IN)	
15:54 - 16:04	Decoding survival expectations: Inguinal vs. Pelvic pN3 - Does location matter? To be confirmed	
16:04 - 16:14	Current treatment patterns and emerging strategies L. Elst, Leuven (BE)	
16:14 - 16:24	After the storm: Evidence-based follow-up in node-positive disease To be confirmed	
16:24 - 16:30	Discussion <i>Panel</i> K. de Ligt, Amsterdam (NL) L. Elst, Leuven (BE) K. Mehra, Bhopal (IN) To be confirmed M.T.A. Vreeburg, Amsterdam (NL) To be confirmed	

Update session II: Bladder cancer

Friday 20 June 15:30 - 16:30	Location	Session room II
	Moderators	J. Aning, Bristol (GB) M.C. Mir Maresma, Valencia (ES) F. Soria, Turin (IT)

Case I To be confirmed

Case II To be confirmed

Muscle invasive bladder cancer

Plenary Session

Friday 20 June 17:15 - 18:45	Location	Auditorium
	Chairs	M.C. Mir Maresma, Valencia (ES) M. Rouprêt, Paris (FR)
17:15 - 17:25	State-of-the-art lecture Unleashing the potential of ctDNA across the spectrum of urothelial Carcinoma To be confirmed	
17:25 - 17:27	Discusssion/Q&A	
17:27 - 17:56	Debate Bladder preservation strategies in MIBC: Feasible standard or a compromise?	
17:27 - 17:30	Case presentation To be confirmed	
17:30 - 17:37	Systemic therapy + RC To be confirmed	
17:37 - 17:44	Systemic therapy + surveillance B.P. Valderrama, Sevilla (ES)	
17:44 - 17:51	Systemic therapy + TMT To be confirmed	
17:51 - 17:56	Discussion	
17:56 - 18:06	State-of-the-art lecture Tips and trick for RARC neobladder formation G. Pignot, Marseille (FR)	
18:06 - 18:08	Discussion	
18:08 - 18:33	Debate Clinically node positive locally advance MIBC: What are the options?	
18:08 - 18:11	Case presentation To be confirmed	
18:11 - 18:18	Systemic therapy + bladder sparing/surveillance B.P. Valderrama, Sevilla (ES)	
18:18 - 18:25	Systemic therapy + RC To be confirmed	
18:25 - 18:33	Discussion	
18:33 - 18:43	State-of-the-art lecture New combinations and concepts of (neo)adjuvant therapy to RC or TMT for MIBC: Thinking outside the box B.P. Valderrama, Sevilla (ES)	
18:43 - 18:45	Discussion	

Update session II: Prostate cancer

Friday 20 June 17:15 - 18:15	Location	Session room II
	Moderators	G. Gandaglia, Milan (IT) L. Rodriguez-Sanchez, Paris (FR)
		To be confirmed

Case I To be confirmed

Case II To be confirmed

Saturday 21 June
08:00 - 09:30

Location

Auditorium

Chairs

To be confirmed

M. Moschini, Milan (IT)

08:00 - 08:10

State-of-the-art lecture **Is there a role of PET-Glu for UTUC staging?**
To be confirmed

08:10 - 08:12

Discussion

08:12 - 08:39

Debate **When should I do diagnostic URS for suspicious UTUC?**

08:12 - 08:15

Case presentation
A. Gallioli, Barcelona (ES)

08:15 - 08:22

Only when in doubt
To be confirmed

08:22 - 08:29

Always do URS
S. Proietti, Milan (IT)

08:29 - 08:39

Discussion

08:39 - 08:49

State-of-the-art lecture **When do I consider segmental ureterectomy**
F. Soria, Turin (IT)

08:49 - 08:51

Discussion

08:51 - 09:01

How to follow up after kidney sparing treatments: Imaging vs. URS
J. Baard, Amsterdam (NL)

09:01 - 09:03

Discussion

09:03 - 09:30

Debate **Is there a role for cytoreductive nephroureterectomy in metastatic UTUC with new first line?**

09:03 - 09:06

Case presentation
D. Raggi, Sutton (GB)

09:06 - 09:13

Yes, do CNuX if partial or complete response
To be confirmed

09:13 - 09:20

No, it doesn't provide an advantage
To be confirmed

09:20 - 09:30

Discussion

Neoadjuvant and adjuvant treatments in genitourinary tumours

European School of Urology (ESU)

Saturday 21 June 08:00 - 10:00	Location	Session room II
	Chair	R. Campi, Florence (IT)
08:00 - 08:05	European School of Urology: A unique possibility for urological education R. Campi, Florence (IT)	
08:05 - 08:15	The role of perioperative therapy in GU cancers B. Szabados, London (GB)	
08:15 - 08:25	Neoadjuvant/adjuvant treatment in renal cancer R. Campi, Florence (IT)	
08:25 - 08:45	Case-based discussion: High-risk localised renal cancer: What would you do? R. Campi, Florence (IT)	
08:45 - 08:55	Neoadjuvant/adjuvant treatment in bladder cancer B. Szabados, London (GB)	
08:55 - 09:15	Case-based discussion: Bladder Cancer. Who needs neoadjuvant and adjuvant therapy? B. Szabados, London (GB)	
09:15 - 09:25	Neoadjuvant/adjuvant treatment in high-risk localized prostate cancer T. Zilli, Bellinzona (CH)	
09:25 - 09:45	Case discussion: Managing high-risk prostate cancer T. Zilli, Bellinzona (CH)	
09:45 - 10:00	Panel discussion: Future of perioperative therapy in GU tumors and take-home messages	

European Oncology Urology Session

Saturday 21 June 09:30 - 10:05	Location	Auditorium
	Chairs	M. Rouprêt, Paris (FR) A. Volpe, Novara (IT)
09:30 - 09:50	Best of Onco-Urology journals	
09:30 - 09:35	Prostate cancer G. Marra, Turin (IT)	
09:35 - 09:40	Urothelial cancer A. Ślusarczyk, Warsaw (PL)	
09:40 - 09:45	Rare tumours To be confirmed	
09:45 - 09:50	Renal cancer T. Kuusk, London (GB)	
09:50 - 10:00	European Urology Oncology lecture To be confirmed To be confirmed	
10:00 - 10:05	European Urology Oncology award Best paper of the year 2024 To be confirmed	

Renal cancer II: Locally advanced and metastatic

Plenary Session

Saturday 21 June 10:30 - 12:15	Location	Auditorium
	Chairs	A. Bex, London (GB)
		To be confirmed
10:30 - 11:00	Trials & updates: Renal cancer advanced and metastatic	
10:30 - 10:40	To be confirmed To be confirmed	
10:40 - 10:50	To be confirmed To be confirmed	
10:50 - 11:00	Discussion	
11:00 - 11:15	State-of-the-art lecture Noadjuvant systemic treatment for advanced kidney cancer: Where are we heading? G.D. Stewart, Cambridge (GB)	
11:15 - 11:30	Society of Urologic Oncology (SUO) lecture Delayed cytoreductive nephrectomy after systemic therapy: When is it indicated? To be confirmed	
11:30 - 11:40	State-of-the-art lecture Progressive disease after adjuvant pembrolizumab: Which is the best systemic treatment option? To be confirmed	
11:40 - 11:50	Discussion	
11:50 - 12:15	Panel discussion Management of progressive disease after adjuvant treatment for RCC	
	Case presenter	R. Campi, Florence (IT)
	Panel	To be confirmed To be confirmed To be confirmed G.D. Stewart, Cambridge (GB)

Real-world UROncology: Challenging the guidelines

Saturday 21 June 10:30 - 12:00	Location	Session room II
	Chairs	J. Aning, Bristol (GB) A. Stenzl, Tübingen (DE) A. Volpe, Novara (IT)
10:30 - 11:00	Diagnosis and active surveillance	
10:30 - 10:37	What do the guidelines recommend? P. Cornford, Cork (IE)	
10:37 - 10:44	What is done in my practice? To be confirmed	
10:44 - 10:51	Solution pathfinder R. Van Den Bergh, Rotterdam (NL)	
10:51 - 11:00	Discussion and sum-up	
11:00 - 11:30	Treatment and training for localised prostate cancer	
11:00 - 11:07	What do the guidelines recommend? To be confirmed	
11:07 - 11:14	What is done in my practice? M. Hora, Plzen (CZ)	
11:14 - 11:21	Solution pathfinder J. Gómez Rivas, Madrid (ES)	
11:21 - 11:30	Discussion and sum-up	
11:30 - 12:00	Multidisciplinary management of mHSPC/CRPC	
11:30 - 11:37	What do the guidelines recommend? To be confirmed	
11:37 - 11:44	What is done in my practice? P. Rajwa, Warsaw (PL)	
11:44 - 11:51	Solution pathfinder J. Aning, Bristol (GB)	
11:51 - 12:00	Discussion and sum-up	

Prostate cancer IV

Plenary Session

Saturday 21 June 13:00 - 14:30	Location	Auditorium
	Chairs	G. Gandaglia, Milan (IT) F. Sanguedolce, Barcelona (ES)
13:00 - 13:10	State-of-the-art lecture	Role of local treatment in metastatic prostate cancer: A new frontier?
	To be confirmed	
13:10 - 13:20	Discussion	
13:20 - 14:00	Clinical trial corner	
13:20 - 13:30	TALAPRO-2	To be confirmed
13:30 - 13:40	ENZA-p	To be confirmed
13:40 - 14:00	Case discussion: Trials put in practice	
	Case presenter	G. Gandaglia, Milan (IT)
	Panel	To be confirmed
		To be confirmed
		To be confirmed
14:00 - 14:30	Clinical case discussion	High-risk biochemical recurrence after radical prostatectomy with negative PSMA PET imaging: How to manage?
14:00 - 14:05	Clinical case presentation	L. Rodriguez-Sanchez, Paris (FR)
14:05 - 14:30	Panel discussion	
	Panel	P. Albers, Düsseldorf (DE)
		I. Burger, Baden (CH)
		G. De Meerleer, Leuven (BE)

UROonco25: Take-home messages

Saturday 21 June 14:45 - 15:15	Location	Auditorium
	Chair	A. Volpe, Novara (IT)
14:45 - 14:52	Urothelial cancer J.L. Domínguez Escrig, Valencia (ES)	
14:52 - 14:59	Renal cancer R. Campi, Florence (IT)	
14:59 - 15:06	Prostate cancer L. Rodriguez-Sanchez, Paris (FR)	
15:06 - 15:15	Rare tumours C. Protzel, Schwerin (DE)	